The LNO attests to Circulus' ability to create 100% recycled PCR appropriate for direct food-contact packaging applications through its recycling process in Riverbank, California
Circulus secures LNO from the FDA to produce PCR at its Riverbank facility. (Credit: Eduardo Soares on Unsplash)
Post-consumer resin (PCR) producer Circulus has secured a Letter of Non-Objection (LNO) from the US Food and Drug Administration (FDA) to produce post-consumer resins at its facility in Riverbank, California.
The LNO attests to Circulus’ ability to create 100% recycled PCR appropriate for direct food-contact packaging applications through its recycling process in its facility.
According to the firm, direct contact applications for frozen, refrigerated, and room-temperature commodities are acceptable for food packaging.
Circulus founder and chief strategy officer David Hudson said: “From its inception, Circulus has been committed to the goal of producing resin for consumer-facing products and packaging.
“This development provides important and independent validation that we have achieved our goal, allowing us to move forward in this important market for recycled materials.”
The PCR maker is one of the portfolio companies of Ara Partners, a private equity organisation that focuses on decarbonisation investments.
Circulus CEO Craig Foster said: “This is a huge step forward for Circulus, the circular economy, and for the sustainable packaging industry.
“Our customers want mechanically recycled resin suitable for the broadest use of applications and Circulus now has the ability to meet this demand.”
Headquartered in Houston, Texas, the firm converts plastic waste into post-consumer resins (PCR) by using mechanical recycling solutions.
The PCR producer recycles plastics to their highest and best use while eliminating waste to help achieve a circular economy. It currently has facilities in development across the US.